ALGS — Aligos Therapeutics Share News
0.000.00%
Last trade - 00:00- $29.85m
- -$0.47m
- $2.19m
Brief: Aligos Therapeutics Strengthens Senior Leadership Team With The Appointment Of Hardean Achneck, MD As Chief Medical Officer
Aligos' fatty liver disease treatment meets main goal in mid-stage study
Aligos Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Aligos Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Aligos Therapeutics Announces Clinical Collaboration With Xiamen Amoytop Biotech
Brief: Aligos Therapeutics Inc - On May 29, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
Aligos Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
Aligos Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Aligos Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Aligos Therapeutics Presents Positive Clinical Data At Hep-Dart 2023 From Phase 1 Studies In Hbv (Alg-000184) And Nash (Alg-055009)
Brief: Aligos Therapeutics Files Prospectus Related To Resale From Time To Time Of Up To 168.7 Million Shares Of Common Stock, By Selling Securityholders
Brief: Aligos Therapeutics Presents Clinical, Nonclinical Data Demonstrating Alg-055009 Has Favorable Risk-Benefit Profile
U.S. RESEARCH ROUNDUP- Pioneer Natural Resources,Oxford Industries, Nutrien
Aligos Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aligos Therapeutics Q3 EPS USD -0.41
Aligos Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Aligos Therapeutics Announces $92 Million Private Placement Financing